HALF MOON BAY, Calif., March 22 /PRNewswire/ -- Saegis Pharmaceuticals, Inc., a biopharmaceutical company focused on developing medicines that protect and enhance memory and cognition, today announced the commencement of a Phase II clinical study of the company's lead product candidate, SGS742, for adult patients with Attention Deficit Hyperactivity Disorder (ADHD).
"Given the prevalence of ADHD and the lifetime impairment faced by people living with this condition, novel therapeutics that are effective in treating this disease are a welcome addition to the known armamentarium for practitioners," commented Timothy E. Wilens, M.D., Associate Professor of Psychiatry, Harvard Medical School and Staff, Pediatric Psychopharmacology Clinic, Massachusetts General Hospital, on the Saegis clinical trial.
SGS742 is a selective GABAB receptor antagonist that has shown improvement in attention and memory in prior clinical studies. The current clinical trial is a placebo-controlled, double-blind crossover study, where patients will be randomized to receive either placebo or active drug, and then crossed over to the alternate agent. The Phase II trial will measure improvement in standard adult attention deficit disorder scales. Saegis expects to complete this trial in the third quarter of this year.
"In preclinical and clinical studies, SGS742 has consistently shown positive benefits on the ability to improve attention, learning and memory," said Rodney Pearlman, Ph.D., President and CEO of Saegis. "We are excited to be conducting an efficacy study among the adult ADHD population where safe, non-stimulatory medicines are needed to control the devastating symptoms that compromise the quality of life of adults living with this condition."
Often, adults with ADHD are unaware that they suffer from this disease unless they were diagnosed in childhood. According to the National Institute of Mental Health, it is estimated that 30 to 70 percent of children with Attention Deficit Hyperactivity Disorder will still suffer from its symptoms as adults. Symptoms of adult ADHD include poor or short attention span, mood swings, distractibility and impulsive behavior. Untreated adults with ADHD are at higher risks for lifestyle issues including employment and relationship difficulties, and may suffer from depression associated with their inability to concentrate on everyday tasks.
SGS742, Saegis' lead compound, is currently in multi-center, randomized Phase II clinical studies for the treatment of mild to moderate Alzheimer's disease. Saegis has reported positive findings from a previously completed Phase II clinical trial of SGS742 in Mild Cognitive Impairment. Results from this trial demonstrated that patients treated with SGS742 exhibited improvements in multiple cognitive domains, including psychomotor skills, attention and memory. In addition, SGS742 has been found to be safe and well tolerated among adults. SGS742 has shown the ability to enhance learning in multiple animal models in preclinical evaluation.
About Saegis Pharmaceuticals
Saegis Pharmaceuticals is a pioneer in the development of medicines that protect and enhance the function of the human mind. Saegis is building a portfolio of compounds for the treatment of neurological conditions that impact memory and cognition, including Alzheimer's disease, mild cognitive impairment and Cognitive Impairment Associated with Schizophrenia (CIAS). Currently, the Company has three orally-available small molecule compounds in clinical development, two of which have already demonstrated efficacy and safety in humans. Saegis' product pipeline is fueled by the discovery and identification of high-value leads leveraging comparative modeling technology of age-related cognitive decline, coupled with the strategic in-licensing and repositioning of promising clinical-stage compounds. Privately held, Saegis has received investment support from Versant Ventures, Technology Partners, Sofinnova Ventures (U.S.), Sofinnova Partners (Paris), Polaris Venture Partners, NeuroVentures, the Stanley Medical Research Institute and Novartis Pharma AG. For more information, visit http://www.saegispharma.com/.
Saegis Pharmaceuticals, Inc.
CONTACT: Jack Anthony of Saegis Pharmaceuticals, Inc., +1-650-560-0210,ext. 259, or email@example.com; or Karen L. Bergman, +1-650-575-1509,or Michelle Corral, +1-415-794-8662, both of BCC Partners, for SaegisPharmaceuticals, Inc.